1. Psoriasis

Category Archives: Psoriasis

Prayer Against Growths; Tumors, Cysts, Polyps, Warts, Moles, Fungus, Psoriasis – Video

Posted on by


Prayer Against Growths; Tumors, Cysts, Polyps, Warts, Moles, Fungus, Psoriasis
Specific prayer against growths in the body, whatever they may be; tumors, cysts, polyps, warts, moles, tags, fungus, psoriasis and the like. https://www.fac...

By: UnforgettableLife

Visit link:

Prayer Against Growths; Tumors, Cysts, Polyps, Warts, Moles, Fungus, Psoriasis - Video

Tampa dermatologists clinical trial for nail psoriasis generating encouraging results

Posted on by

Tampa Dermatologist Dr. Seth Forman is expressing boundless optimism as the clinical trial for nail psoriasis his office in conducting is producing astounding results

Reformulated to specifically treat nail psoriasis, the medication Humira is being used in phase III of a clinical trial. Humira is an already available medication known to relieve pain and to reduce inflammation in a number of autoimmune diseases, including psoriasis.

Throughout the trials, the reformulated version of the medication has been given to patients in order to monitor and confirm its effectiveness. So far, the Tampa dermatologist says hes impressed with the findings.

We are happy with what weve seen so far, said Dr. Forman. This is by far the most effective nail psoriasis treatment Ive ever seen. The results are that spectacular.

The condition is a common feature seen in conjunction with cutaneous psoriasis and psoriatic arthritis. Nail psoriasis can affect as much as 50 percent of all psoriasis patients, causing distress from pain and an unsightly look, according to the Psoriasis Institute.

While the ongoing nail psoriasis clinical trials continue to move along fluidly, Dr. Forman says they are far from being over.

The trials are still in the beginning phases and there is still a lot of work to be done, said the Tampa dermatologist. We aim to continue treating patients, both new and current, until we are fully satisfied with the outcome.

Dr. Formans office offers multiple clinical trials for eczema, plaque psoriasis nail psoriasis and others. Clinical trials offer patients, insured or not, the opportunity for complimentary healthcare.

If interested in being a part of the clinical trial for nail psoriasis, or for more on Dr. Seth Forman, Tampa dermatology or Forman Dermatology and Skin Cancer Institute, please visitwww.FormanDerm.com.

About Dr. Seth Forman:Dr. Forman is a board-certified dermatologist practicing in Tampa, Florida. He was voted the Best Dermatologist in Carrollwood in 2011 and 2012 by the Carrollwood News and Tribune. In December 2011, he opened his newTampa dermatologyoffice, Forman Dermatology and Skin Cancer Institute, where he gives psoriasis sufferers access to the latest treatment options, including topical and oral medications, as well as biological and phototherapy. Dr. Forman is one of the few Tampa dermatologists to offer narrowband light therapy, which uses pharmaceutical grade light to suppress psoriasis. Hes also one of the few board-certified dermatologists in the U.S. to use the SRT-100 radiotherapy to treat basal cell carcinoma, the most common form of skin cancer.

See the rest here:

Tampa dermatologists clinical trial for nail psoriasis generating encouraging results

AbbVie's HUMIRA (Adalimumab) Receives Positive CHMP Opinion to Treat Children and Adolescents With Severe Chronic …

Posted on by

Marketing Authorization Decision Expected from the European Commission in the Second Quarter

NORTH CHICAGO, Illinois, Feb. 27, 2015 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced that the European Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted a positive opinion for HUMIRA (adalimumab) for the treatment of severe chronic plaque psoriasis in children and adolescents from four years of age. If granted marketing authorization by the European Commission, HUMIRA may become the first treatment availablefor severe chronic plaque psoriasisin children and adolescents fromfour years of age who have had an inadequate response to or are inappropriate candidates for topical therapy and phototherapies.

"The positive response from the CHMP marks an important step in addressing the needs of children and adolescents living with severe plaque psoriasis in Europe," said Michael Severino, M.D., executive vice president, research and development and chief scientific officer, AbbVie. "Building on more than 16 years of clinical experience with HUMIRA, we look forward to the opportunity to make a positive impact on the lives of pediatric plaque psoriasis patients."

The positive opinion is based on the results of a Phase 3 study, which will be presented at an upcoming medical meeting. The review of the marketing authorization application (MAA) is being conducted under the centralized licensing procedure. If approved, the authorization will be valid in all 28 member states of the European Union, as well as Iceland, Liechtenstein and Norway.

Since first gaining approval 12 years ago, HUMIRA has been approved in more than 87 countries. It is currently being used to treat more than 843,000 patients worldwide1 across 10 globally approved indications.2

About Pediatric Chronic Plaque Psoriasis According to estimates from the World Health Organization, pediatric psoriasis occurs in 0.70 percent of the pediatric population,3 with no significant difference by gender.4 The chronic autoimmune disease is characterized by the rapid and excessive accumulation of skin cells, which form thick patches of inflamed, scaly skin.5 Pediatric psoriasis has similar characteristics to adult psoriasis, but in children, the psoriatic lesions are typically smaller, thinner, and less scaly.4 Beyond the physical challenges of managing the chronic skin disorder, it is also considered to have significant emotional and psychological effects.6

HUMIRA EU Therapeutic Indications2 HUMIRA is approved for use in moderate to severe rheumatoid arthritis, active juvenile idiopathic arthritis in patients who have had inadequate response to prior therapy, ankylosing spondylitis, moderate to severe plaque psoriasis, active and progressive psoriatic arthritis, moderate to severely active Crohn's Disease and moderate to severely active ulcerative colitis.See SmPC for full indication.

Important EU Safety Information2 HUMIRA is contraindicated in patients with active tuberculosis or other severe infections and in patients with moderate to severe heart failure. The use of HUMIRA increases the risk of developing serious infections which may, in rare cases, be life-threatening. Rare cases of lymphoma and leukemia have been reported in patients treated with a TNF-antagonist. On rare occasions, a severe type of cancer called hepatosplenic T-cell lymphoma has been observed and often results in death. A risk for the development of malignancies in patients treated with TNF-antagonists cannot be excluded. The most frequently reported adverse events across all indications included respiratory infections, injection site reactions, headache, abdominal pain, nausea, rash and musculoskeletal pain.

(see SmPC for full details at https://www.medicines.org.uk/emc/medicine/21201)

About AbbVie AbbVie is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott Laboratories. The company's mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases. AbbVie employs more than 26,000 people worldwide and markets medicines in more than 170 countries. For further information on the company and its people, portfolio and commitments, please visit http://www.abbvie.com. Follow @abbvie on Twitter or view careers on our Facebook or LinkedIn page.

Continue reading here:

AbbVie's HUMIRA (Adalimumab) Receives Positive CHMP Opinion to Treat Children and Adolescents With Severe Chronic ...

Marshaling the body's own weapons against psoriasis

Posted on by

A three-character code brings relief to patients with psoriasis and sheds light on complex immunoregulation processes: IL-4, an abbreviation for the endogenous signaling molecule Interleukin 4. The substance's ability to inhibit inflammation is well known, but its mechanism of action was not fully understood. Scientists from the Technische Universitt Mnchen (TUM) and the University of Tbingen have now shown in an animal model and in a study on patients exactly how IL-4 helps against psoriasis at the molecular level and the important role it plays in our immune system.

Inflammation is a defense strategy of the body against invaders. Increased amounts of blood and fluid flow into the infected areas, and the release of signaling molecules summon immune cells to the site of infection to effectively neutralize the pathogens. However, poorly coordinated or misdirected immune reactions can trigger inflammation even in the absence of external agents, thus causing undue tissue damage. This is the case in psoriasis and other autoimmune diseases, such as multiple sclerosis and rheumatoid arthritis.

The body's own signaling molecule as a therapy candidate

"Together with colleagues from Tbingen, we were able to show in earlier studies that the signaling molecule IL-4 is a promising candidate for the treatment of psoriasis," explains Prof. Tilo Biedermann, who holds the chair for Dermatology and Allergology and is Director of the Clinic and Polyclinic for Dermatology and Allergology. "However, before IL-4 can be used as a standardized medication, we have to understand the exact mechanism of action -- and we've now succeeded in doing just that."

The scientists followed a translational approach in their study -- the laboratory findings were applied to patients without delay. They first used human and mouse cells to unravel the molecular effects of IL-4 on inflammation. To this effect, the scientists discovered that IL-4 inhibits specific immune cells in a natural way: it prevents the cells from synthesizing and releasing two signaling molecules, known as IL-23 and IL-17.

"The discovery is very interesting in that IL-23 activates special T-cells in the body, thus triggering inflammation. Evidently IL-4 is able to effectively block this pathway," says Biedermann. In subsequent experiments with mice, the scientists also found that administration of IL-4 specifically inhibits inflammation of the skin via this mechanism.

IL-4 reduces psoriasis in patients

The scientists also checked the findings from the animal model in a patient study. Twenty-two patients with psoriasis received subcutaneous injections of IL-4 over a period of six weeks. Tilo Biedermann and his colleagues then examined samples from the patients' affected skin areas before and after the treatment.

The results confirmed the previous experiments: Before treatment with IL-4, the study participants had high levels of IL-23 and IL-17 in their inflamed and itchy skin. After successful treatment, the two substances were barely detectable. The result was that inflammation and psoriatic skin changes had disappeared.

"Our study results show that IL-4 very selectively and successfully suppresses inflammation. This therapeutic approach could therefore be very interesting for the treatment of other autoimmune diseases," explains Biedermann. "Moreover, we now have a better understanding of how IL-4 functions as an important 'checkpoint' in the immune system and will be able to better appreciate and exploit its significance in the future."

Read more:

Marshaling the body's own weapons against psoriasis

First independent U.S. psoriasis registry will track drug safety and effectiveness

Posted on by

PORTLAND, Ore., Feb. 26, 2015 /PRNewswire-USNewswire/ -- People with psoriasis and their health care providers will have the opportunity to participate in research that aims to improve treatments and disease outcomes when the first independent U.S. psoriasis registry begins recruiting patients in 2015.

The registry, a joint collaboration with the National Psoriasis Foundation and Corrona, LLC, will initially track the drug safety reporting for secukinumab, a new biologic medication by Novartis Pharmaceuticals for moderate-to-severe psoriasis. The Corrona Psoriasis Registry will enroll at least 3,000 people with psoriasis on secukinumab and follow their treatment for at least eight years. Novartis is the first subscriber to the registry and did incur a subscriber fee.

To become an investigator in the registry or learn more about it, visit http://www.psoriasis.org/corrona-registry.

By collecting and analyzing data from thousands of people with psoriasis over many years, the registry will help clinicians, researchers and the pharmaceutical industry compare the effectiveness and safety of different psoriasis treatments. Data will be gathered through comprehensive questionnaires completed by patients and their dermatologists during appointments.

"Psoriasis therapies have improved greatly over the years, yet there still remains an important need for us to understand more about their long-term safety and the course of disease over a patient's lifetime," said Dr. BruceStrober, vice chair of UConn Health's department of dermatology and scientific director for the registry. "This registry will help determine which treatments are safest and most effective for psoriasis in the long term."

In addition to studying treatment safety and effectiveness, the registry will help identify possible causes of psoriasis, examine the relationship between psoriasis and other health conditions, and study the impact of the disease on quality of life, among other outcomes.

"Post approval studies such as the Corrona Psoriasis Registry that collect standardized data on newly approved therapies and comparator drugs are needed to provide patients and clinicians, as well as regulators and payors, with real world evidence on long-term comparative effectiveness and safety," said Dr. Jeff Greenberg, chief scientific officer with Corrona and clinical associate professor of medicine at NYU School of Medicine.

Psoriasisa painful, chronic, genetic disease that causes the skin to crack, itch and bleedis the most common autoimmune disease in the country, affecting up to 7.5 million Americans. People with psoriasis are at increased risk for heart disease, heart attack, stroke, diabetes, obesity and depression. Up to 30 percent of psoriasis patients develop psoriatic arthritis, an inflammatory joint and tendon disease.

Learn more about the psoriasis registry and how you can participate at http://www.psoriasis.org/corrona-registry.

About the National Psoriasis FoundationNational Psoriasis Foundation (NPF) is the world's largest nonprofit serving those with psoriasis and psoriatic arthritis. Our priority is to provide the services people need to take control of their condition, while increasing research to find a cure. In addition to serving more than 2.1 million people annually through our education and advocacy initiatives, NPF has funded more than $10 million in psoriatic disease research grants and fellowships. Learn more at http://www.psoriasis.org or call 800.723.9166. Follow us on Facebook and Twitter.

Here is the original post:

First independent U.S. psoriasis registry will track drug safety and effectiveness

Psoriasis Treatments Review and Bonus Package Launched December 12, 2014 – Video

Posted on by


Psoriasis Treatments Review and Bonus Package Launched December 12, 2014
Health News PR publishes a dedicated page and exclusive bonus package to coincide with this effective treatment for psoriasis sufferers. http://news.massmediaseo.com/psoriasis-treatments-revie...

By: MassMedia

Excerpt from:

Psoriasis Treatments Review and Bonus Package Launched December 12, 2014 - Video

Woman with psoriasis claims supermarket bosses asked her to leave after customers complained about her scars

Posted on by

A WOMAN who suffers from a painful skin condition says she was asked to leave a supermarket after complaints from customers about her appearance.

Psoriasis sufferer Kate Dalessio, 58, was told fellow shoppers in Sainsbury's had commented about scarring on her arms and claims the manager asked her to leave.

Angry Kate has accused the supermarket giants of treating her like a shoplifter and plans to sue.

But store bosses deny asking her to leave and say they were only trying to defuse an ugly situation as the shoppers who complained were getting more aggressive.

Managers insist they were only trying to protect Kate until the other shoppers had left and say she is welcome back any time.

The incident happened as Kate was out with her sister Alessandria, 59, at the Sainsburys store in Meadowbank, Edinburgh.

She says that she was taken to the duty managers office before being escorted out of the store in front of staff and customers.

Kate said: The duty manager told me that there had been complaints from two customers that I was being offensive.

He explained that they objected to the state of my arms.

I was wearing a sleeveless top and you could see the scarring my condition causes. The manager then took me downstairs back through the store in front of everyone to the exit.

Read the rest here:

Woman with psoriasis claims supermarket bosses asked her to leave after customers complained about her scars

Researchers find gene that confirms existence of psoriatic arthritis

Posted on by

Researchers led by the Arthritis Research UK Centre for Genetics and Genomics at The University of Manchester have identified genetic variants that are associated with psoriatic arthritis (PsA) but not with psoriasis, in the largest study of PsA ever published.

PsA is a common form of inflammatory form of arthritis causing pain and stiffness in joints and tendons that can lead to joint damage. Nearly all patients with PsA also have skin psoriasis and, in many cases, the skin disease is present before the arthritis develops. However, only one third of patients with psoriasis will go on to develop PsA.

The researchers, who are part of a European consortium, say that their work, which took three years to complete and is published in Nature Communications, is a breakthrough because genetic changes have been identified that increase the risk of PsA but not psoriasis.

Until recently opinion was divided as to whether psoriatic arthritis was a disease in its own right, or psoriasis combined with rheumatoid arthritis.

The findings could, in future, lead to the identification of people with psoriasis who are at risk of developing psoriatic arthritis.

Dr John Bowes, who led the analysis of the work, said: "Our study is beginning to reveal key insights into the genetics of PsA that explain fundamental differences between psoriasis and PsA. Our findings also highlight that CD8+ cells are likely to be the key drivers of inflammation in PsA. This will help us to focus on how the genetic changes act in those immune cells to cause disease."

The gene identified by the research team lies on chromosome 5 and is not the first PsA-specific gene to be identified. Patients who carry the HLA-B27 gene are also more likely to develop PsA.

Professor Anne Barton, a rheumatologist and senior author on the study explained: "By identifying genes that predispose people to PsA but not psoriasis, we hope in the future to be able to test patients with psoriasis to find those at high risk of developing PsA. Excitingly, it raises the possibility of introducing treatments to prevent the development of PsA in those individuals in the future."

Dr Stephen Simpson, director of research at Arthritis Research UK added:" This is a significant finding. Not only does it help establish PsA as a condition in its own right, but it could have major implications in the way that patients with this condition are treated and lead to the development of drugs specifically developed for PsA, which are greatly needed."

The research was funded by the National Institute for Health Research Manchester Musculoskeletal Biomedical Research Unit.

Go here to read the rest:

Researchers find gene that confirms existence of psoriatic arthritis


  1. Psoriasis